AbbVie Reports Second-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
William Blair Remains Bullish on AbbVie (ABBV) Following 2Q Beat
July 30, 2018 8:45 AM EDTWilliam Blair reiterated an Outperform rating and $127.00 price target on Abbvie (NYSE: ABBV) following the company's 2Q earnings report. Revenues for the quarter were $8.3 billion, beating consensus of $8.2 billion. Non-GAAP EPS were $2.00, above consensus of $1.97.
Management issued updated guidance for 2018 non-GAAP EPS of $7.76 to $7.86... More
Abbvie (ABBV) PT Lowered to $110 at Cowen
July 27, 2018 11:57 AM EDTCowen lowered its price target on Abbvie (NYSE: ABBV) to $110.00 (from $130.00) while maintaining an Outperform rating following beat and raise.
The firm is lowering the target based on a reduced target PE of 14x 2018 EPS (prior 17x) given lingering uncertainties (legal, pricing,... More
AbbVie (ABBV) Tops Q2 EPS by 3c, Offers FY Guidance
July 27, 2018 7:39 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $2.00, $0.03 better than the analyst estimate of $1.97. Revenue for the quarter came in at $8.28 billion versus the consensus estimate of $8.21 billion.
GUIDANCE:
AbbVie sees FY2018 EPS of $7.76-$7.86, versus the consensus of $7.81.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More